PDGFRA signaling actively remodels the glioma microenvironment, contributing to vascular abnormalities (e.g., via the PDGFRA-Endocan-MYC axis), metabolic reprogramming that impairs T cell function, and immune cell polarization, all of which restrict anti-tumor immunity. Here, ESM1 is linked to neoplasm.